Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-08-2014 | Award Amount: 22.57M | Year: 2015
Cancer is a worldwide health burden and represents a major public health challenge in Europe. It is responsible for 25% of all deaths, being the second most common cause of death after cardio-vascular diseases and the main cause of mortality among people aged 4564. Today, an estimated 9 million individuals in Europe live with cancer (Globocan 2008, http://globocan.iarc.fr/). Cancer became a chronic disease which contributed substantially to the growth of medical expenditures and constitutes a major socio-economic challenge for Europe as well as globally. A rapid and effective bidirectional transfer of relevant cancer research findings between bench and bedside would play a pivotal role in addressing top-priority needs at the EU level to reduce incidence and mortality of malignancies and to improve the quality of life of cancer patients. The proposed ERA-NET Cofund TRANSCAN-2, in continuity with the preceding and ongoing TRANSCAN ERA-NET, aims at linking translational cancer research funding programmes in 15 Member States, 3 Associated Countries, and a third country. By concentrating transnational resources, TRANSCAN-2 will provide a critical financial and scientific mass for tackling large-scale problems, relevant for improving translational cancer research globally. A co-funded joint transnational call (JTC) will be launched focusing on the topic Intratumour heterogeneity in resistance to therapy and recurrence followed by three additional JTCs that will be implemented in a frame of multinational translational cancer research programmes. In addition, strategies will be developed for the enlargement of the network, for improvement of coordination and for an efficient communication and dissemination of the results of the consortium as well as of the research projects funded through the JTCs. The monitoring of the projects funded through the JTCs and the critical assessment of the performance of TRANSCAN-2, based on key indicators, will be also realised.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-11-2015 | Award Amount: 20.88M | Year: 2016
The ERA-NET NEURON Cofund will coordinate and align European and international research funding programmes in the area of brain-related diseases and disorders of the nervous system. Key activity is the implementation of an EC co-funded joint transnational call for research proposals. The mission of NEURON is based on the fact that disorders of the brain are the major cause for impaired quality of life, and they are a heavy burden not only for patients, their families and carers, but also a socioeconomic problem for society. By improving collaboration and by implementing a variety of additional activities (such as further joint transnational calls and support of early-career scientists) NEURON Cofund will decrease fragmentation of research programmes and improve the funding situation for neuroscience researchers thereby strengthening the search for novel therapeutic approaches to fight brain disease; NEURON Cofund will also develop and provide concrete plans for (i) expanding data sharing, (ii) promoting common data elements for the establishment of patient registries, and (iii) involving stakeholders and relevant existing initiatives such as patient organizations. The aforementioned challenges will be addressed in a network of 22 funding organizations across 14 European Member and Associated States and Third countries.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-12-2015 | Award Amount: 23.81M | Year: 2015
Antibiotic resistance is a global problem. It is considered by the World Health Organization as one of the three greatest threats to human health for the next decades. Enhanced coordination across national boundaries is needed to accelerate the efforts to tackle this grand challenge. Such synergies have been created among 19 countries in Europe and beyond through the EU JPI on Antimicrobial Resistance (JPIAMR). JPIAMR has developed a Strategic Research Agenda (SRA) which defines the strategic and scientific priorities benefiting from co-ordination and co-operation at the European level and mobilised national funds for two joint transnational calls (JTC) 2014 and 2015 based on this. In the ERA-NET Cofund JPI-EC-AMR, an additional 23 million of national funds will be combined with a highly incentivising EC top-up fund to support a new transnational research programme. The aim of this programme is to unravel the complex dynamics of selection and transmission of antimicrobial resistance (AMR) according to the One Health concept. A multidisciplinary approach is necessary to identify and characterise the determinants that contribute to the spread of resistance at genetic, bacterial, animal, human, societal, and environmental levels, in order to provide scientific knowledge to design and evaluate cost-effective strategies that can decrease transmission of AMR in society. JPI-EC-AMR will launch additional JTCs without EC co-funding under the framework of the SRA. and perform additional joint actions in close collaboration with JPIAMR actions. JPI-EC-AMR will provide a better, quantitative understanding of drug-resistant bacteria in animals, foods, and the environment and to what extent they contribute to the burden of antibiotic-resistant infections in humans. Research in this area is crucial in order to provide the robust scientific evidence needed to make informed decisions regarding interventions and policy measures in hospital, community, and agricultural settings.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: ISIB-12e-2015 | Award Amount: 15.98M | Year: 2016
This proposal seeks funding under the Horizon 2020 Work Programme 2014-2015 to establish an ERA-NET for joint European research coordination on Sustainable Animal Production (SusAn). The scope for this ERA-NET has been developed under the SCAR Collaborative Working Group on Sustainable Animal Production (CWG-SAP). Funding organisations from 22 European countries initially seek to support one co-funded call followed by other joint activities including the development of a Common Strategic Research and Innovation Agenda on Sustainable Animal Production. The animal production sector forms an important part of Europes (agricultural) economy and plays an essential role in the provision of Europe`s citizens with high quality animal products. Like other agriculture sectors, animal production faces many challenges from projected increases in global demand for food, climate change, competition for natural resources and economic volatility. The European animal production landscape is very complex, consisting of different species farmed within a wide range of different extensive, semi-intensive and intensive production systems using multiple resources to produce a diverse range of animal products and other services. Partners in this ERA-NET believe, however, that these challenges and complexities can be effectively addressed through joint European research within a framework which supports the three pillars of sustainability - economy, environment and society - and targets opportunities for innovative research spanning all areas of animal production such as health and welfare, feeding and nutrition, reproduction, breeding and genetics, housing, nutrient management and economics. Partners in ERA-NET SusAn endorse scientific excellence and recommend an integrated, interdisciplinary, cross-cutting and multi-actor approach to research and knowledge exchange which reflects the complexity of the research requirements for sustainable European animal production.
Agency: European Commission | Branch: H2020 | Program: COFUND-EJP | Phase: SC1-PM-05-2016 | Award Amount: 74.06M | Year: 2017
The overarching goal of the European Human Biomonitoring Initiative (HBM4EU) is to generate knowledge to inform the safe management of chemicals and so protect human health. We will use human biomonitoring to understand human exposure to chemicals and resulting health impacts and will communicate with policy makers to ensure that our results are exploited in the design of new chemicals policies and the evaluation of existing measures. Key objectives include: Harmonizing procedures for human biomonitoring across 26 countries, to provide policy makers with comparable data on human internal exposure to chemicals and mixtures of chemicals at EU level; Linking data on internal exposure to chemicals to aggregate external exposure and identifying exposure pathways and upstream sources. Information on exposure pathways is critical to the design of targeted policy measures to reduce exposure; Generating scientific evidence on the causal links between human exposure to chemicals and negative health outcomes; and Adapting chemical risk assessment methodologies to use human biomonitoring data and account for the contribution of multiple external exposure pathways to the total chemical body burden. We will achieve these objectives by harmonizing human biomonitoring initiatives in 26 countries, drawing on existing expertise and building new capacities. By establishing National Hubs in each country to coordinate activities, we will create a robust Human Biomonitoring Platform at European level. This initiative contributes directly to the improvement of health and well-being for all age groups, by investigating how exposure to chemicals affects the health of different groups, such as children, pregnant women, foetuses and workers. We will also investigate how factor such as behavior, lifestyle and socio-economic status influence internal exposure to chemicals across the EU population. This knowledge will support policy action to reduce chemical exposure and protect health.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-13-2015 | Award Amount: 19.10M | Year: 2015
Cardiovascular diseases (CVD) are the largest cause of death in the EU and account for around 2 million deaths per year. Overall, CVD are estimated to cause the economy of the EU costs of almost 196 billion Euros a year. Furthermore, they are one of the leading causes of long term sickness, chronic diseases and loss to the labour market. Therefore, CVD are a major health problem in Europe. Despite the overall burden of CVD on European citizens and national health systems, translational cardiovascular research is fragmented and mainly occurs at national levels. However, the present and future challenges in cardiovascular research can only be met by an effective cooperation at transnational level. Therefore, the proposed European Research Area Network on cardiovascular diseases (ERA-CVD) aims to coordinate national and regional programmes for translational research in the area CVD by implementing one Joint Transnational Call (JTC2016) with EU Co-funding followed by further non-co-funded JTC (2017-2019). Although this consortium will be newly established, a collaboration and alignment of national programmes and activities has already been achieved during the preparation of the ERA-Net Co-fund proposal. This process is supported by CardioScape an EU-funded survey of the European cardiovascular research landscape coordinated by the European Society of Cardiology (ESC). The current ERA-CVD proposal will extend and strengthen the transnational cooperation of the current 23 ministries/institutions/foundations from 18 European, associated and third countries. Furthermore, ERA-CVD plans to cooperate with the ESC and the European Heart Network (EHN). Moreover, the collaboration with European Research Infrastructures, e.g. the ESFRI-initiatives is intended in order to set up an efficient European framework for innovative transnational research on CVD. Also the extension of the consortium and international collaborations are intended.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: NMBP-11-2016 | Award Amount: 15.27M | Year: 2016
Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: SFS-25-2016 | Award Amount: 2.12M | Year: 2016
The overall objective of CASA is a consolidated common agricultural and wider bioeconomy research agenda within the European Research Area. The common research agenda will be jointly shared by Member States of the European Union and Associated Countries. It will improve the alignment and interoperability of the respective national research programme(s). This will be achieved through enhanced cooperation, coordination and information exchange between the Member States, Associated Countries and the European Commission. This includes increasing the opportunities for Member States and Associated Countries to engage in the aforementioned activities. The conduit for this will be the Standing Committee of Agricultural Research (SCAR) and the various SCAR working groups, through which all Member States and Associated Countries are brought together with a view to fostering cooperation, coordination and information exchange, as well as streamlining research policy, in the bioeconomy and closely related fields. The overarching aim of CASA will be achieved through the accomplishment of the following four specific objectives: 1. Increased and broadened participation, interaction and collaboration of Member States and Associated Countries 2. Improved quality of outputs and outcomes of the Standing Committee of Agricultural Research creating added value for greater impact 3. Strengthening the production of more strategic policy advice by the Standing Committee of Agricultural Research based on the increased, deepened and broadened participation facilitated by CASA 4. Improve overall organisation, communication and dissemination of SCAR activities, outputs and outcomes for greater impact
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: SC1-HCO-06-2016 | Award Amount: 2.04M | Year: 2016
In order to strengthen the sustainability and resilience of health services and systems a unique consortium of governmental and funding organizations plus research institutes, has expressed the ambition to systematically learn from the organisation of care in other settings. Overall objective of TO-REACH is to provide groundwork for an ERA-NET that will contribute to the resilience, effectiveness, equity, accessibility and comprehensiveness of health services and systems. We will do so along two work streams: A) We will develop a research program on cross-border learning from good (or even innovative) models of care and the conditions needed to transfer them to other settings for implementation. It could refer to anywhere in the care chain depending on the priorities as identified in a Strategic Research Agenda (SRA) within this project. Conceptual, methodological and empirical advancement will be achieved through 4 meta-questions that will instruct research under the ERA-NET, linking to what counts as good models of care, what are the conditions required for transferability, what are the conditions for up-scaling, and how do they contribute to the performance of health care organisations and systems. B) We will build a platform for funding organizations that allows for collaboration and coordination in the project and projected ERA-NET. This will synchronize priorities and activities, hence improving the quality and applicability of research with a focus on the topic areas as described under A. TO-REACH will pursue five specific objectives: Mapping health system challenges and priorities by synthesizing different materials and stakeholder inputs; Developing a framework and providing a knowledge synthesis on the above-mentioned meta-questions; Establishing sustainable cooperation of research funding bodies and links with other initiatives; Developing a SRA through agenda setting at European and Member State level; Disseminating the results of TO-REACH.
Agency: European Commission | Branch: H2020 | Program: ERA-NET-Cofund | Phase: HCO-07-2014 | Award Amount: 30.95M | Year: 2015
Over 12 million people in Europe suffer from neurodegenerative diseases (ND), yet treatments that prevent or stop the progression of neurodegeneration are still lacking. Tackling this grand challenge requires enhanced coordination of national efforts to accelerate discovery. Such synergies have been created among 28 countries in the pilot EU JPI on Neurodegenerative Disease Research (JPND). JPND has a long standing experience in collaborative action with 75 million of additional national funds being successfully mobilized between 2011 and 2014 to support transnational research programs. The JPND Research Strategy is now ripe for further enhancement in tight coordination with the EC through an ERA-Net Cofund instrument JPco-fuND with an unprecedented commitment of 30 million of national funds associated to a highly incentivizing EC top-up fund. Among the most burning questions, three priority topics have emerged through a consultative process between researchers and JPND members in order to unlock several major issues within ND research: the identification of genetic, epigenetic and environmental risk and protective factors, the development and maintenance of longitudinal cohorts, the creation of advanced experimental models. These are key questions of equal priority to increase understanding of ND mechanisms that will be addressed through a common joint transnational call allowing a significant acceleration of the execution of the JPND research strategy. Moreover, to expand the impact of JPco-fuND, JPND will continue to implement other actions without EU co-funding such as aligning national research strategies, making databases more accessible and interoperable, developing enabling capacities such as supportive infrastructure and platforms, capacity building, education and training. These actions are required in parallel to achieve the highest impact for the patients, their carers and for society as whole and address this grand challenge in the coming years.